Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Provention Bio Inc's Business Segments
Provention Bio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/PRVB/segments
https://api.csimarket.com/api/v1/companies/PRVB/geographic
https://api.csimarket.com/api/v1/companies/PRVB/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Annual Results
Revenue by Product & Service Category -
- Collaboration Revenues90.8%
- Product9.2%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenues | $ 12 | 90.8% |
| Product | $ 1 | 9.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Provention Bio Inc
Provention Bio Inc is a biopharmaceutical company focused on the development of innovative therapies aimed at preventing and intercepting immune-mediated diseases. The company is based in Oldwick, New Jersey, and was founded in 2016.
Provention Bio utilizes advanced scientific approaches to identify and advance potential therapeutics that have the ability to modulate the immune system and prevent the onset or progression of diseases. Their research primarily targets autoimmune diseases, such as type 1 diabetes, Crohn's disease, and lupus. These diseases occur when the immune system mistakenly attacks the body's own cells and tissues.
One of the main areas of focus for Provention Bio is the development of novel therapies to prevent or delay the onset of type 1 diabetes (T1D). They aim to identify individuals who are at high risk of developing the disease and intervene before it fully manifests. They have been conducting clinical trials for their lead candidate, teplizumab, which has shown promising results in delaying the progression of T1D in patients.
In addition to T1D, Provention Bio is actively working on developing treatments for other autoimmune diseases. For example, they are exploring the potential of PRV-031, an anti-interleukin-15 monoclonal antibody, for the treatment of gluten-free diet non-responsive celiac disease, a condition in which patients are unable to tolerate gluten despite adhering to a gluten-free diet.
Provention Bio also focuses on preventing the progression of recently diagnosed type 1 diabetes through the development of PRV-015, an investigational monoclonal antibody targeting the B-cell activating factor (BAFF). They believe that targeting BAFF could preserve beta-cell function and improve clinical outcomes in patients with T1D.
In addition to their pipeline of novel therapeutics, Provention Bio is actively involved in strategic collaborations and partnerships with academia, clinical research organizations, and industry experts. Through these collaborations, they aim to leverage expertise and resources to advance their research and development programs.
Overall, Provention Bio Inc is a biopharmaceutical company dedicated to developing innovative preventive and interception therapies for immune-mediated diseases, with a particular focus on type 1 diabetes and other autoimmune disorders. Their approach aims to modulate the immune system and prevent or delay the onset of these diseases, ultimately improving patient outcomes and quality of life.
Provention Bio utilizes advanced scientific approaches to identify and advance potential therapeutics that have the ability to modulate the immune system and prevent the onset or progression of diseases. Their research primarily targets autoimmune diseases, such as type 1 diabetes, Crohn's disease, and lupus. These diseases occur when the immune system mistakenly attacks the body's own cells and tissues.
One of the main areas of focus for Provention Bio is the development of novel therapies to prevent or delay the onset of type 1 diabetes (T1D). They aim to identify individuals who are at high risk of developing the disease and intervene before it fully manifests. They have been conducting clinical trials for their lead candidate, teplizumab, which has shown promising results in delaying the progression of T1D in patients.
In addition to T1D, Provention Bio is actively working on developing treatments for other autoimmune diseases. For example, they are exploring the potential of PRV-031, an anti-interleukin-15 monoclonal antibody, for the treatment of gluten-free diet non-responsive celiac disease, a condition in which patients are unable to tolerate gluten despite adhering to a gluten-free diet.
Provention Bio also focuses on preventing the progression of recently diagnosed type 1 diabetes through the development of PRV-015, an investigational monoclonal antibody targeting the B-cell activating factor (BAFF). They believe that targeting BAFF could preserve beta-cell function and improve clinical outcomes in patients with T1D.
In addition to their pipeline of novel therapeutics, Provention Bio is actively involved in strategic collaborations and partnerships with academia, clinical research organizations, and industry experts. Through these collaborations, they aim to leverage expertise and resources to advance their research and development programs.
Overall, Provention Bio Inc is a biopharmaceutical company dedicated to developing innovative preventive and interception therapies for immune-mediated diseases, with a particular focus on type 1 diabetes and other autoimmune disorders. Their approach aims to modulate the immune system and prevent or delay the onset of these diseases, ultimately improving patient outcomes and quality of life.
Provention Bio Inc. is a biopharmaceutical company that specializes in developing innovative therapies focused on immune-mediated diseases, particularly autoimmune diseases and food allergies. The company aims to address unmet medical needs through a science-driven approach, emphasizing precision medicine.
Segments
Provention Bio primarily operates in the biopharmaceutical sector, with a key focus on:
1. Autoimmune Diseases: This segment targets disorders where the immune system wrongly attacks the body’s own tissues. The company develops therapies that can modulate immune responses and improve patients quality of life.
2. Food Allergies: Another crucial focus is on therapies for food allergies, specifically for conditions like peanut allergy, which can have severe and life-threatening implications for affected individuals.
3. Infectious Diseases: While less prominent than autoimmune diseases and food allergies, the company has ventures in developing treatments that can enhance the immune response against specific infections.
Products
Provention Bios most notable product is Teplizumab, a groundbreaking therapy approved for the delaying of type 1 diabetes in at-risk individuals. This product is a humanized anti-CD3 monoclonal antibody that works by modulating the immune system to prevent the progression of diabetes in those who have not yet developed the disease but are at high risk.
- Teplizumab (Tzield): This product is designed to be administered in a series of doses to delay the onset of clinical Type 1 diabetes in individuals aged eight years and older. The approval of Teplizumab is significant as it is the first drug that modifies the course of type 1 diabetes.
Services
While Provention Bio is primarily focused on drug development, its services may include:
1. Clinical Trials: The company conducts extensive clinical trials to test the safety and efficacy of its drugs, involving collaboration with medical professionals and research institutions.
2. Regulatory Support: Provention Bio engages in partnership with regulatory bodies to ensure compliance and adherence to guidelines necessary for the approval of new drugs, handling all aspects of regulatory submissions.
3. Patient Support Programs: To enhance patient access to therapies, Provention Bio may provide resources and support initiatives aimed at educating patients and healthcare providers about their therapies, managing side effects, and assisting with financial access.
4. Research Collaborations: The company often partners with academic and research institutions to expand its pipeline and leverage external expertise for compound discovery and development.
5. Outreach and Advocacy: Provention Bio is involved in raising awareness regarding autoimmune diseases and food allergies through collaborations with organizations and advocacy groups, aiming to educate the public and healthcare professionals on the importance of early diagnosis and intervention.
Overall, Provention Bio Inc. is positioned at the forefront of developing innovative therapies aimed at managing complex immune-mediated conditions, with a commitment to improving patient outcomes through scientific research and development.
Segments
Provention Bio primarily operates in the biopharmaceutical sector, with a key focus on:
1. Autoimmune Diseases: This segment targets disorders where the immune system wrongly attacks the body’s own tissues. The company develops therapies that can modulate immune responses and improve patients quality of life.
2. Food Allergies: Another crucial focus is on therapies for food allergies, specifically for conditions like peanut allergy, which can have severe and life-threatening implications for affected individuals.
3. Infectious Diseases: While less prominent than autoimmune diseases and food allergies, the company has ventures in developing treatments that can enhance the immune response against specific infections.
Products
Provention Bios most notable product is Teplizumab, a groundbreaking therapy approved for the delaying of type 1 diabetes in at-risk individuals. This product is a humanized anti-CD3 monoclonal antibody that works by modulating the immune system to prevent the progression of diabetes in those who have not yet developed the disease but are at high risk.
- Teplizumab (Tzield): This product is designed to be administered in a series of doses to delay the onset of clinical Type 1 diabetes in individuals aged eight years and older. The approval of Teplizumab is significant as it is the first drug that modifies the course of type 1 diabetes.
Services
While Provention Bio is primarily focused on drug development, its services may include:
1. Clinical Trials: The company conducts extensive clinical trials to test the safety and efficacy of its drugs, involving collaboration with medical professionals and research institutions.
2. Regulatory Support: Provention Bio engages in partnership with regulatory bodies to ensure compliance and adherence to guidelines necessary for the approval of new drugs, handling all aspects of regulatory submissions.
3. Patient Support Programs: To enhance patient access to therapies, Provention Bio may provide resources and support initiatives aimed at educating patients and healthcare providers about their therapies, managing side effects, and assisting with financial access.
4. Research Collaborations: The company often partners with academic and research institutions to expand its pipeline and leverage external expertise for compound discovery and development.
5. Outreach and Advocacy: Provention Bio is involved in raising awareness regarding autoimmune diseases and food allergies through collaborations with organizations and advocacy groups, aiming to educate the public and healthcare professionals on the importance of early diagnosis and intervention.
Overall, Provention Bio Inc. is positioned at the forefront of developing innovative therapies aimed at managing complex immune-mediated conditions, with a commitment to improving patient outcomes through scientific research and development.